Grafa News and Videos — Page 714

Kamada (NASDAQ:KMDA) announced Monday that the U.S. Food and Drug Administration has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) rabies virus neutralization laboratory at its manufacturing plant in Beit Kama, Israel.

A Chinese real estate executive was killed in Cambodia after his family was unable to pay a $2 million cryptocurrency ransom demanded by kidnappers following his abduction in Phnom Penh.

Marex Group (NASDAQ:MRX) announced Monday that it has acquired Levmet, a Monaco-based liquidity provider, in a move to strengthen its physical market-making operations and secure a firmer foothold in European power and gas trading.

Jade Biosciences (NASDAQ:JBIO) delivered a significant milestone for its autoimmune pipeline, reporting positive interim results from its Phase 1 clinical trial evaluating JADE101.

Monopar Therapeutics (NASDAQ:MNPR) announced encouraging mid-stage clinical results for its investigational Wilson disease therapy, demonstrating widespread stabilization in liver pathology alongside substantial neurological and quality-of-life improvements.

A social media post describing how a farmer earned an 11.5% annualised yield through Strategy’s STRC preferred shares has ignited debate over whether bitcoin-linked income products strengthen or dilute bitcoin’s core principles.

C1 Fund (NYSE:CFND) released its financial results for the first quarter ended March 31, 2026, revealing a net asset value (NAV) of $48,906,337, or $7.34 per share, against a backdrop of accelerating initial public offering activity within its private digital asset portfolio.

Citius Oncology (NASDAQ:CTOR) showcased positive early-stage clinical trial results, demonstrating the potential of its targeted immune therapy LYMPHIR to enhance the efficacy of checkpoint inhibitors in treating recurrent or refractory gynecologic cancers.

Bitgo CEO Mike Belshe warned that Europe’s Markets in Crypto-Assets (MiCA) framework could create systemic risks for stablecoin issuers by forcing reserve assets into traditional banking institutions.

Invivyd (NASDAQ:IVVD) completed enrollment for the pivotal Phase 3 clinical trial of its leading monoclonal antibody candidate, positioning the biotechnology firm to deliver late-stage results later this quarter.